for the treatment of adults with giant cell arteritis (GCA). 1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

Giant cell arteritis (GCA), also known as temporal arteritis, is an autoimmune disease of medium and large arteries, characterized by granulomatous inflammation of the three-layered vessel wall, which ...

RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults – Also known as temporal ... adults with giant cell arteritis ...

The most specific finding is tender or thickened temporal arteries with decreased ... or rarely over the orbits. Giant cell arteritis is a systemic vasculitis and careful attention should be ...

has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta ...

a patient with vasculitis shall be said to have giant cell temporal arteritis if at least three of these five criteria are present. Giant cell arteritis (GCA) is a medical emergency. The concept ...

4. Temporal arteritis: When blood vessels inflame Temporal arteritis, also known as giant cell arteritis, represents one of the more serious causes of one-sided head pain, particularly in adults ...

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA ... Also referred to as temporal arteritis, GCA is ...